RBCC Actively Seeking Joint Venture Partners For Upcoming Canadian Rollouts

HENDERSON, Nev.--(BUSINESS WIRE)--Rainbow Coral Corp. (OTCBB: RBCC) has been aggressively pursuing potential partners for joint venture opportunities related to the company’s proposed Canadian personalized medicine and addiction treatment rollouts. RBCC is seeking to meet with interested parties, including companies as well as medical, governmental and ethnic groups, to discuss collaboration.

“We’ve spent the past several months developing a far-sighted business plan that is now ready to be set into motion”

“We’ve spent the past several months developing a far-sighted business plan that is now ready to be set into motion,” said RBCC CEO Kimberly Palmer. “This plan focuses on medical compounding and expanding our reach into the substance abuse treatment arena, especially opioid addiction. The Canadian personalized medicine, drug compounding and delivery, and addiction treatment markets have shown tremendous upside and positive movement in recent years. We’re eager to find suitable partners with whom we can develop mutually profitable relationships and we’ve been pleased with what we’ve identified thus far.”

Earlier this year, RBCC announced it was nearing agreements to distribute the anti-addiction drug Naltrexone north of the border and to deliver the drug to a Canadian medical group to treat alcohol abuse. Research indicates roughly 11 percent of Canadians are afflicted with alcohol or drug addiction and that Canadian taxpayers face a C$22.8 billion tab each year to combat and treat substance abuse.

On the personalized medicine front, RBCC has been seeking ways to take advantage of its expertise in topical and injectable drug delivery protocols. Canada currently is the world’s ninth-largest pharmaceutical market.

RBCC is dedicated to delivering advanced medical research and technologies to a booming global health marketplace. For more information on RBCC’s initiatives, please visit www.rainbowbiosciences.com.

About Rainbow Biosciences

Rainbow Biosciences, LLC, is a wholly owned subsidiary of Rainbow Coral Corp. (RBCC). The Company continually seeks out new partnerships with biotechnology developers to deliver profitable new medical technologies and innovations. For more information on our growth-oriented business initiatives, please visit www.RainbowBioSciences.com. For investment information and performance data on the Company, please visit www.RainbowBioSciences.com/investors.html.

Notice Regarding Forward-Looking Statements

Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995: This news release contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, including statements that include the words "believes," "expects," "anticipate" or similar expressions. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements of the Company to differ materially from those expressed or implied by such forward-looking statements. In addition, description of anyone's past success, either financial or strategic, is no guarantee of future success. This news release speaks as of the date first set forth above and the Company assumes no responsibility to update the information included herein for events occurring after the date hereof.